PB101 plus EGFR-TKI including gefitinib, erlotinib, afatinib, or osimertinib
PB-2018-V12
Phase 1 mab completed
Quick answer
PB101 plus EGFR-TKI including gefitinib, erlotinib, afatinib, or osimertinib for Non-small Cell Lung Cancer is a Phase 1 program (mab) at PRECISION BIOSCIENCES INC with 1 ClinicalTrials.gov record(s).
Program details
- Company
- PRECISION BIOSCIENCES INC
- Indication
- Non-small Cell Lung Cancer
- Phase
- Phase 1
- Modality
- mab
- Status
- completed